Navigation Links
Alzheimer's Drug Discovery Foundation Funds American Life Science Pharmaceuticals, Inc to Move Novel Therapeutic Towards Clinic
Date:5/24/2010

NEW YORK, May 24 /PRNewswire-USNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF) announced today that it is providing a grant of $248,000 to American Life Science Pharmaceuticals, Inc. (ALSP) to allow for manufacture of its lead drug candidate to be used in preclinical toxicology testing in preparation for entering Phase I clinical trials early in 2011.

ALSP is developing new methods to effectively treat neurodegenerative disease with an initial focus on Alzheimer's disease (AD). ALSP has identified a new class of drugs that prevent memory deficit and pathology in animal models of AD. "Our proprietary lead compound, AB-007, has previously been evaluated for a different indication in human clinical trials and shown to be safe and well tolerated," said company CEO, Michael D. Pierschbacher, PhD. "Our goal is to conduct clinical trials on AB-007 to confirm as soon as possible the observed preclinical efficacy for treatment of AD."

ALSP was recently awarded a National Institute on Aging (NIA) contract to pay for all Investigational New Drug (IND)-enabling toxicology and pharmacology studies. "This ADDF grant combined with the NIA contract makes it possible for us to move this promising Alzheimer's drug through toxicology testing toward the clinic at maximum speed," said Greg Hook, PhD, JD, an ALSP founder. ALSP is currently launching aggressive efforts to raise Series A financing.

ALSP's technology comes out of Vivian Hook, PhD's laboratory at the UCSD Skaggs School of Pharmacy and Pharmaceutical Sciences. Dr. Hook discovered that a novel target enzyme may be responsible for the production of the majority of the beta amyloid peptide in sporadic Alzheimer's disease.  

"The ultimate test for any investigational treatment is in human trials," said the ADDF's executive director, Howard Fillit, MD. "This ADDF grant accelerates AB-007 into clinical testing."

For more information about the ADDF or to speak with Dr. Fillit, please contact Diana Shineman, PhD at 212-901-8007 or dshineman@alzdiscovery.org.  For information about ALSP, Inc. or to speak with Dr. Michael Pierschbacher, call 858-273-3900 or e-mail info@alspinc.com.

About the Alzheimer's Drug Discovery Foundation (www.AlzDiscovery.org)

The ADDF is the only public charity whose sole mission is to accelerate the discovery and development of drugs to prevent, treat and cure Alzheimer's disease, related dementias and cognitive aging. Since 1998, the ADDF has granted more than $40 million to fund over 295 Alzheimer's drug discovery programs in academic centers and biotechnology companies in 15 countries. 

About American Life Science Pharmaceuticals, Inc. (www.alspinc.com)

ALSP is a privately held company located in San Diego, CA. The company and its world class team is passionate about finding a drug that prevents the devastation that is Alzheimer's disease.  We believe that our lead candidate, AB-007, represents a first-in-class drug that has an excellent chance to meet that challenge. ALSP is poised to enter the crucible of the clinic to put its approach to the test.


'/>"/>
SOURCE Alzheimer's Drug Discovery Foundation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
2. New Company Starts, Bridging the Development Gap in the Discovery of Cancer Drugs
3. Trana Discovery and Southern Research Institute Announce the First RNA-RNA High Throughput Drug Screening Assay Platform for HIV Antivirals
4. ActiveSight and CHDI Leverage Fragment-Based Lead Discovery for Huntington Disease Therapies
5. ARCA Discovery Announces Data Demonstrating Potential for Bucindolol as Targeted Therapy in Heart Failure, Atrial Fibrillation, and Ventricular Arrhythmia
6. Five Clinical Studies to Receive $2.5 Million Under Foundations 2007 Clinical Discovery Program
7. Ambrx Enters FGF-21 Type 2 Diabetes Drug Discovery Collaboration with Merck and Co. Inc.
8. FASgen Announces New Discovery for Treatment of Stroke
9. Nobel Prize-Winning Discovery
10. Orion Genomics Announces the Discovery of Novel Breast Cancer Biomarkers
11. FASgen Announces a New Discovery in Obesity Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... , March 24, 2017 New England ... recipient of an award including funding and in-kind service ... draw technology.  "Making blood draws less ... making their whole hospital experience better.  We,re looking forward ... technology can help improve care for the kids we ...
(Date:3/24/2017)... DUBLIN , Mar. 24, 2017 Research and ... Size, Share, Development, Growth and Demand Forecast to 2022" report to ... The global ... expected to grow at a CAGR of 6.7% during 2016-2022 ... segment held the largest share in the global market in 2015. Among ...
(Date:3/24/2017)... Research and Markets has announced the addition of the "Dental ... ... markets for Dental Implants in US$ Million. The report provides separate comprehensive ... , Europe , Asia-Pacific , ... Annual estimates and forecasts are provided for the period 2015 through ...
Breaking Medicine Technology:
(Date:3/27/2017)... ... 2017 , ... SyncDog, Inc. , the leading ISV ... Business Solutions at ATARC Federal Mobile Computing Summit , March 28. The ... and examination into the mobility tools and technology employed by the Federal government ...
(Date:3/27/2017)... ... March 27, 2017 , ... The Case Management Society of America ... June 30, 2017. CMSA’s membership has elected their upcoming President-Elect, Secretary, Treasurer and ... Advisory position, a new VA Advisory position has also been added to the BOD, ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... training, today announced the launch of a new research study, The Business Readiness ... needed to execute that strategy, and the actual success of achieving individual and ...
(Date:3/27/2017)... Mateo, CA (PRWEB) , ... March 27, 2017 , ... Janet Schloz is still in ... of the best days I’ve had in a long time,” she said. , She thinks ... lot of money that I never thought I would have to help my students.” , ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... the launch of a months-long rebranding effort. This includes the introduction of new ... group discussions and market research, we learned that a simple, proactive approach to ...
Breaking Medicine News(10 mins):